Franklin, MA (PRWEB) November 04, 2013
Bed Bug infestations are increasing at an alarming rate and with the difficulty in detecting and eliminating the insects, ZeptoMetrix and CytoSignet have determined that the most effective pest control strategy lies in early detection and post-treatment monitoring.
Bed Bugs feed only on blood throughout their lifespan. After feeding, the parasite seeks harborage to digest, defecate and wait for the next feeding opportunity. It is during its movement to and from hiding places the insect leaves a biochemical trail including fecal matter as evidence of its presence and passage. Hemoglobin and various other biochemical markers are left scattered in the environment providing valuable and readily obtainable footprints of their activities and locations.
Our Partnership's combined technology resulted in multiple patented testing systems taking advantage of the debris left by the insect announcing its existence. The products created by ZeptoMetrix Corporation (ZMC) and CytoSignet, Inc. thereby, allow for easier and more effective detection methods past and present.
Together, our collaboration is an ongoing initiative to provide simple, cost effective and accurate answers to the global Bed Bug Infestation through a better use of science.
Our exciting, new product line includes:
Detection Spray – Bed BugDetect 1
A simple to prepare atomized spray; easily dispensed with hand-held bottle; cost effective; non-toxic; immediate and enhanced visualization of bed bug movement.
On-Site Screening Capabilities – Bed BugDetect 2
A highly sensitive screening test; low cost design; simple and unobtrusive to implement; designed for on-site results by property owners, operation managers and other various, untrained, non-licensed personnel to indicate that blood-feeding on humans has occurred.
Confirmation Tests – Bed BugDetect 3
Debris is collected and analyzed for specific Bed Bug biochemicals including DNA, test can be performed with or without the Detection Spray or On-Site Screening Test.
The technologies discussed above are covered by US Patents No. 7,727,734 and 8,460,890; European Patent No. 1,920,239 B1; Canadian Patent No. 2,621,590 and other patents pending.
For appropriate usage of our patented detection technology, Licensing Agreements are currently available and are being considered.
For more information, please contact:
Michael A. Hershfield, Director, Sales & Marketing
Read the full story at http://www.prweb.com/releases/2013/11/prweb11297365.htm.
Copyright©2012 Vocus, Inc.
All rights reserved